One way to prevent the effect of a molecule is to use the cell’s own machinery to break it down. This is what the PROTAC technology does, an acronym for proteolysis targeting chimera, or BacPROTAC, when applied to bacteria. A study led by Austrian and German scientists has demonstrated the effectiveness of this technique in eliminating the tuberculosis pathogen Mycobacterium tuberculosis (Mtb). The finding opens the door to the BacPROTAC strategy as an alternative to the development of drugs against this microorganism. Read More
By analyzing a cohort of adolescents that developed myocarditis or pericarditis after vaccination against SARS-CoV-2 vaccination, researchers from Yale University School of Medicine were able to pinpoint the underlying mechanism as an overly active innate immune response to the vaccine that led to broad activation of T cells and natural killer (NK) cells. Myocarditis “has been seen in other vaccine contexts, though is most common after viral infection,” Carrie Lucas told reporters at a press conference announcing the findings.
Read More
Scisparc Ltd.’s drug discovery joint venture, Mitocarex Bio, has successfully developed its core algorithm for allowing the generation of reliable... Read More
There is still a lack of specific biomarkers in biliary epithelial cells of patients with primary sclerosing cholangitis (PSC). Investigators from the... Read More
IL-18 is a pro-inflammatory cytokine that triggers IFN-γ production and increases T- and NK-cell activity. IL-18’s effects are blocked by IL-18 binding protein (IL-18BP), an endogenous protein that binds to IL-18 with high affinity and that is highly present in the tumor microenvironment (TME). Read More
Compounds reported to be useful for the treatment of myotonic 1, myotonic 2 and muscular dystrophy have been described in a City University of New York patent. Read More
Data on the poly(ADP-ribose) glycohydrolase (PARG) inhibitor SYX-3759, being investigated for the treatment of homologous recombination deficient (HRD) malignancies, were recently discussed by researchers from Hangzhou Synrx Therapeutics Technology Co. Ltd. Read More
Replacing the damaged cell population in neurodegenerative diseases provides a treatment approach. However, interventions that protect host cells could offer new treatment possibilities for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s diseases and amyotrophic lateral sclerosis (ALS). Read More
Cullgen (Shanghai) Inc. has patented proteolysis targeting chimera (PROTAC) compounds comprising a DDB1 binding moiety covalently bonded to a target protein binding moiety through a linker. They are reported to be useful for the treatment of cancer. Read More
Halia Therapeutics Inc. has reported the development of tyrosine-protein kinase receptor TYRO3 inhibitors potentially useful for the treatment of glioma. Read More
Researchers from TYK Medicines Inc. have reported the discovery and preclinical evaluation of TY-1091, a second-generation RET inhibitor being developed for the treatment of RET-mutant cancers. Read More
